Clinical outcome

Effect of polymorphisms of vascular endothelial growth factor on prognosis in osteosarcoma patients

X. D. Li, Yu, D. D., Lu, J. R., Wu, C., and Jin, W. X., Effect of polymorphisms of vascular endothelial growth factor on prognosis in osteosarcoma patients, vol. 14, pp. 4354-4360, 2015.

We investigated the association between vascular endothelial growth factor (VEGF) gene +1612G/A, -634C/G, and +936G/C and the clinical outcome of osteosarcoma. Genomic DNA was isolated from blood samples, and 3 VEGF gene polymorphisms (+1612G/A, -634C/G, and +936G/C) were analyzed using polymerase chain reaction-restriction fragment length polymorphism. Of the 194 patients, 82 patients (42.27%) showed a good response to chemotherapy, while 73 (37.63%) died during the follow-up period.

B-type natriuretic peptide and cirrhosis progression

L. Y. Shi, Jin, R., Lin, C. J., Wu, J. S., Chen, X. W., Yu, Z., and Zhang, P. C., B-type natriuretic peptide and cirrhosis progression, vol. 14, pp. 5188-5196, 2015.

Brain natriuretic peptide (BNP) is used as a marker of cardiac dysfunction to predict heart failure mortality. The significance of the prognostic ability of BNP for liver cirrhosis remains unknown, although the levels of BNP seen in cirrhosis are high. We aimed to determine whether the BNP level is related to the stage of cirrhosis and could serve as a prognostic marker of cirrhosis (predict the 1-year all-cause mortality). We recruited 92 patients at different stages of cirrhosis and 81 controls matched by age and gender for this study.

Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy

J. Z. Li, Tian, Z. Q., Jiang, S. N., and Feng, T., Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy, vol. 13, pp. 3186-3192, 2014.

We conducted a comprehensive study to investigate the role of genes involved in metabolic and transport pathways in response to chemotherapy and clinical outcome of osteosarcoma patients. Genotyping of seven gene polymorphisms was performed on a 384-well plate format on the Sequenom MassARRAY platform in 162 patients with osteosarcoma. We studied the correlation of the seven gene polymorphisms with response to chemotherapy and clinical outcome of patients.

Implication of polymorphisms in DNA repair genes with an increased risk of hepatocellular carcinoma

J. S. Wu, Chen, Y. P., Wang, L. C., Yang, Y. J., Deng, C. W., Hou, B. X., He, Z. L., and Chen, J. X., Implication of polymorphisms in DNA repair genes with an increased risk of hepatocellular carcinoma, vol. 13, pp. 3812-3818, 2014.

We explored the association between 4 XRCC1 (Arg194Trp and Arg399Gln) and XPD (Asp312Asn and Lys751Gln) polymorphisms with the development and prognosis of hepatocellular carcinoma (HCC). A total of 218 cases with HCC and 277 healthy controls were included in the study. Genotyping of the XRCC1 (Arg194Trp and Arg399Gln) and XPD (Asp312Asn and Lys751Gln) polymorphisms was performed in a 384-well plate format on the Sequenom MassARRAY platform.

Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer

J. G. Liang, Jin, Z. Y., Gao, X. D., Te, M. R., Ge, L. H., and Wang, C. L., Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer, vol. 13, pp. 5292-5298, 2014.

This study aimed to evaluate the association between RRM1 and BRCA1 expressions and the therapeutic efficacy of platinum-based chemotherapy in non-small cell lung cancer patients in terms of their response and prognosis. In total, 377 patients agreed to participate in our study, and all of them received platinum-based combination chemotherapy between January 2008 and January 2009.

Polymorphisms of vascular endothelial growth factor on prognosis in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization treatment

J. Song, Wang, L. Z., Li, X., Jiang, T. P., An, T. Z., Xu, M., Wu, X. P., and Zhou, S., Polymorphisms of vascular endothelial growth factor on prognosis in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization treatment, vol. 13, pp. 8946-8953, 2014.

We conducted a cohort study to investigate the prognostic significance of vascular endothelial growth factor (VEGF) polymorphisms in hepatocellular carcinoma (HCC) patients after transcatheter arterial chemoembolization (TACE). In total, 156 patients with histologically confirmed HCC within 2 months were collected from January 2007 to January 2008. The genotypes of VEGF-2578C/A, -1154G/A, -634C/G, and -1498T/C were determined from blood extracted using a blood kit on a 384-well plate. The survival rate at 5 years was 55.47%.

Association between p53 codon 72 polymorphisms and clinical outcome of nasopharyngeal carcinoma

M. L. Li, Dong, Y., Hao, Y. Z., Xu, N., Ning, F. L., Chen, S. S., and Yu, J. M., Association between p53 codon 72 polymorphisms and clinical outcome of nasopharyngeal carcinoma, vol. 13, pp. 10883-10890, 2014.

We conducted a cohort study to investigate whether polymorphisms in p53 at codon 72 are associated with tumor response and survival time of advanced nasopharyngeal carcinoma (NPC) patients treated with radiotherapy. The study population included 127 subjects with NPC who were enrolled at Binzhou Medical University between September 2008 and December 2009. Cox proportional hazard regression was used to assess the association between polymorphisms in the p53 gene and progression-free survival (PFS) and overall survival (OS) of NPC patients.

Subscribe to Clinical outcome